Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

2yrs ago Cannabis hightimes Views: 436

Canadian cannabis producer Aurora Cannabis Inc. announced on July 15 that it officially delivered one of the largest shipments of cannabis to Israel to date.

The company completed a record-breaking delivery defined as “nearly C$8 million”—one of the company’s largest shipments. “We are excited about the evolution of the cannabis industry in Israel and commend the Ministry of Health and the Israeli Medical Cannabis Agency for ensuring thoughtful regulation of cannabis, in the best interest of Israeli cannabis patients,” said Chief Executive Officer of Aurora Cannabis Inc. Miguel Martin.

He continued, “We look forward to continuing to provide high-quality cannabis to Israel, as part of our strategy to expand our medical cannabis portfolio in key international markets.”

Aurora Cannabis Inc. has been supplying Israel-based Cantek Global Ltd., a leading medical cannabis enterprise, with dried cannabis flower for a few months now, through a strategic supply agreement that the two company’s established with one another. The agreement, which was officially announced in November 2020, requires a minimum of 4,000kg of bulk dried flower to be shipped annually to Israel for a total of two years with the option to extend later.

In a press statement, Martin praised the two companies’ opportunity to expand their international cannabis brands and make history. “It’s about the strength and quality of the Aurora medical brand being validated once again by the world’s medical cannabis markets, including countries like Israel in which we had no distribution prior to today. We consider this Agreement to be a significant step for Aurora, and we look forward to bringing our high-quality medical cannabis products to patients in Israel.” Cantek Global Ltd. has partnerships with “local drugstores chains, distribution companies, clinics.”

Aurora Cannabis is an International Cannabis Brand

Aurora Cannabis Inc., a big player in the Canadian cannabis industry, as well as throughout the world, has also become a large producer of flower for the German cannabis market as well, despite need to cull part of its European workforce back in July 2020. On May 25, the company officially began trading on The Nasdaq Global Select Market under the ticker symbol “ACB” (which is separate from its listing on the Toronto Stock Exchange as “TSX: ACB”).

In June, the company was interviewed by BNN Bloomberg regarding its push for unique genetics in order to stand out from other Canadian competition. “We have a lot of great genetics that we can work on but we’re already moving beyond what we had,” said Aurora’s Senior Vice President of Science and Innovation Charles Pick. “We’re taking plants that are already super interesting and we’re crossing them and being able to produce hundreds, if not thousands of seeds.”

Like many cannabis companies, Aurora released a statement in support of the United States’ recently proposed federal cannabis bill. “The introduction of the Cannabis Administration and Opportunity Act is a watershed moment for cannabis-related public policy in the United States. Aurora welcomes this proposed legislation and what its passage would mean for the health, wellbeing, and livelihoods of millions of Americans—especially communities of colour and all those disproportionately affected by cannabis prohibition, punitive penalties, and linger stigma,” the company wrote on Twitter.

“As one of Canada’s—and the world’s—largest licensed cannabis producers, Aurora is no stranger to a regulatory undertaking that’s national in scope. We’re ready and willing to work with legislators in the United States on making continued progress towards cannabis policies that prioritize safety, wellbeing, justice, and common sense. With the introduction of this legislation, we are hopeful that cannabis policy will continue to evolve in the United States, and will soon reflect the American public’s overwhelming support for legalization.”

Aurora Cannabis Company Delivers Record-Breaking $8 Million in Cannabis Product to Israel on High Times.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.